Table 2.
Number (%) of cases and controls, Ors, and 95% CIs by leukemia subgroup for MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, SHMT1 1420C>T, TS 1494del6, and TS 28-bp repeat
| Controls, n (%) | MLL |
TEL-AML1 |
Hyperdiploidy |
||||
|---|---|---|---|---|---|---|---|
| n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | ||
| Total* | 824 | 34 | 103 | 316 | |||
| MTHFR (677 C>T) | |||||||
| CC | 359 (47.2) | 13 (44.8) | 1.00 | 38 (42.2) | 1.00 | 124 (45.9) | 1.00 |
| CT | 317 (41.7) | 12 (41.4) | 1.05 (0.47-2.32) | 36 (40.0) | 1.07 (0.66-1.73) | 117 (43.3) | 1.07 (0.80-1.43) |
| TT | 84 (11.1) | 4 (13.8) | 1.32 (0.42-4.14) | 16 (17.8) | 1.80 (0.96-3.38) | 29 (10.8) | 1.00 (0.63-1.60) |
| CC versus CT/TT | 401 (52.8) | 16 (55.2) | 1.10 (0.52-2.32) | 52 (57.8) | 1.23 (0.79-1.91) | 146 (54.1) | 1.05 (0.80-1.39) |
| MTHFR (1298A>C) | |||||||
| AA | 350 (46.1) | 16 (55.2) | 1.00 | 56 (62.2) | 1.00 | 137 (50.9) | 1.00 |
| AC | 332 (43.7) | 8 (27.6) | 0.53 (0.22-1.25) | 28 (31.1) | 0.53 (0.33-0.85)a | 109 (40.5) | 0.84 (0.63-1.12) |
| CC | 77 (10.2) | 5 (17.2) | 1.42 (0.51-1.40) | 6 (6.7) | 0.49 (0.20-1.17) | 23 (8.6) | 0.76 (0.46-1.27) |
| AA versus AC/CC | 409 (53.9) | 13 (44.8) | 0.70 (0.33-1.47) | 34 (37.8) | 0.52 (0.33-0.81)b | 132 (49.1) | 0.82 (0.62-1.09) |
| SHMT1 (1420C>T) | |||||||
| CC | 351 (46.1) | 15 (48.4) | 1.00 | 35 (38.5) | 1.00 | 148 (52.7) | 1.00 |
| CT | 318 (41.8) | 13 (41.9) | 0.96 (0.45-2.04) | 44 (48.3) | 1.39 (0.87-2.22) | 98 (34.9) | 0.73 (0.54-0.98) |
| TT | 92 (12.1) | 3 (9.7) | 0.76 (0.22-2.69) | 12 (13.2) | 1.31 (0.65-2.62) | 35 (12.4) | 0.90 (0.58-1.39) |
| CC versus CT/TT | 410 (53.9) | 16 (51.6) | 0.91 (0.45-1.87) | 56 (61.5) | 1.37 (0.88-2.14) | 133 (47.3) | 0.77 (0.58-1.01) |
| TS 28-bp repeat† | |||||||
| 2R/2R | 181 (23.9) | 3 (10.3) | 1.00 | 20 (24.7) | 1.00 | 70 (26.4) | 1.00 |
| 2R/3R | 368 (48.7) | 14 (48.3) | 2.30 (0.65-8.09) | 40 (49.4) | 0.98 (0.56-1.73) | 116 (43.8) | 0.82 (0.58-1.15) |
| 3R/3R | 205 (27.1) | 12 (41.4) | 3.53 (0.98-12.71) | 21 (25.9) | 0.93 (0.49-1.77) | 79 (29.8) | 1.00 (0.68-1.46) |
| 2R/2R versus all others | 575 (76.1) | 26 (89.7) | 2.73 (0.82-9.12) | 61 (75.3) | 0.96 (0.56-1.63) | 195 (73.6) | 0.88 (0.64-1.21) |
| TS (1494 del6) | |||||||
| 6-bp+/6-bp+ | 373 (49.0) | 18 (54.5) | 1.00 | 55 (56.7) | 1.00 | 137 (47.7) | 1.00 |
| 6-bp+/6-bp− | 331 (43.4) | 10 (30.3) | 0.63 (0.28-1.38) | 34 (35.1) | 0.70 (0.44-1.10) | 114 (39.7) | 0.94 (0.70-1.25) |
| 6-bp−/6-bp− | 58 (7.6) | 5 (15.2) | 1.79 (0.64-5.00) | 8 (8.2) | 0.94 (0.42-2.06) | 36 (12.6) | 1.69 (1.07-2.68)c |
| 6-bp+/6-bp+ versus 6-bp+/6-bp−/6-bp−/6-bp− | 389 (51.0) | 15 (45.5) | 0.80 (0.40-1.61) | 42 (43.3) | 0.73 (0.48-1.12) | 150 (52.3) | 1.05 (0.80-1.38) |
| MTR 2756 (A>G) | |||||||
| AA | 510 (67.2) | 12 (41.4) | 1.00 | 58 (59.8) | 1.00 | 181 (60.5) | 1.00 |
| AG | 223 (29.4) | 14 (48.3) | 2.67 (1.21-5.86)d | 34 (35.1) | 1.34 (0.85-2.11) | 101 (33.8) | 1.28 (0.96-1.71) |
| GG | 26 (3.4) | 3 (10.3) | 4.90 (1.30-18.45)e | 5 (5.1) | 1.69 (0.63-4.57) | 17 (5.7) | 1.84 (0.98-3.47) |
| AA versus AG/GG | 249 (32.8) | 17 (58.6) | 2.90 (1.36-6.17)f | 39 (40.1) | 1.37 (0.88-2.14) | 118 (39.1) | 1.34 (1.01-1.76)g |
OR indicates odds ratio.
*
Total includes cases for whom a result was not available, and varied between single nucleotide polymorphisms.
†
Includes 3 controls with 3R/4R genotype.
aP = .01, bP = .001, cP = .02, dP = .01, eP = .02, fP = .006, gP = .04.